News

Altimmune: Upcoming MASH Data Could Be High Impact For Business Development Activity
Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.
Altimmune (ALT) Stock Rises Amid Clinical Trial Progress: What's Going On?
Altimmune stock rose on Tuesday without news, possibly due to high short interest. Its new trial for Alcohol Use Disorder and ...
Viking Therapeutics: Obesity Candidates Must Prove Their Edge As Market Matures (Upgrade)
Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled ...
Could Altimmune, Inc. (ALT): Analysts See 288% Upside Potential
We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Altimmune, Inc. (NASDAQ:ALT) was one of ...
Morningstar10d
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...
Investing10d
Altimmune begins phase 2 trial for AUD treatment
Altimmune’s Chief Medical Officer, Dr. Scott Harris, noted the potential of GLP-1 agents like pemvidutide to reduce alcohol cravings, referencing preclinical studies showing significant ...
Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital
Term loan adds balance sheet strength and provides financial flexibility to support continued development of pemvidutideGAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT ...
Finanznachrichten10d
Altimmune, Inc: Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
About Altimmune Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company's lead ...